PathWhiz

PathWhiz ID	Pathway	Meta Data
PW145656 View Pathway	drug action Tirbanibulin Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 16:19 Last Updated: October 07, 2023 at 16:19
PW122410 View Pathway	drug action Tirofiban Action Homo sapiens Tirofiban is a platelet aggregation inhibitor drug sold under the name Aggrastat. It is specifically a small molecule that inhibits the glycoprotein IIb/IIIa receptor of platelets. It is administered intravenously, and can act to decrease platelet aggregation by over 90% after the infusion, and can help prevent aggregation for up to two days after administration. In the vein, tirofiban causes a conformational change in the integrins on the surface of activated platelets. This prevents the binding of fibrinogen to these integrins, which in turn prevents the platelets from being held together by these fibrinogen fibres. The conformational change also prevents the binding of von Willebrand factor to the platelets, which also prevents aggregation and adhesion. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Eponine Oler Created On: March 25, 2019 at 21:24 Last Updated: March 25, 2019 at 21:24
PW000293 View Pathway	drug action Tirofiban Action Pathway Homo sapiens Tirofiban is a platelet aggregation inhibitor drug sold under the name Aggrastat. It is specifically a small molecule that inhibits the glycoprotein IIb/IIIa receptor of platelets. It is administered intravenously, and can act to decrease platelet aggregation by over 90% after the infusion, and can help prevent aggregation for up to two days after administration. In the vein, tirofiban causes a conformational change in the integrins on the surface of activated platelets. This prevents the binding of fibrinogen to these integrins, which in turn prevents the platelets from being held together by these fibrinogen fibres. The conformational change also prevents the binding of von Willebrand factor to the platelets, which also prevents aggregation and adhesion. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: WishartLab Created On: August 22, 2013 at 10:45 Last Updated: August 22, 2013 at 10:45
PW128069 View Pathway	drug action Tirofiban Action Pathway (new) Homo sapiens Tirofiban is a platelet aggregation inhibitor, also known under the brand name Aggrastat, it is used to prevent thrombotic events from occurring in those who are high-risk. It is administered intravenously and acts as an antagonist of the platelet glycoprotein IIb/IIIa receptor, this receptor is responsible for platelet aggregation in order to form a thrombus, without this signal from the receptor it stops aggregation. This inhibition created by the drug will cease once the drug is no longer infused into the patient's bloodstream. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Selena Created On: July 13, 2023 at 09:38 Last Updated: July 13, 2023 at 09:38
PW144884 View Pathway	drug action Tirofiban Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 14:38 Last Updated: October 07, 2023 at 14:38
PW146190 View Pathway	drug action Titanium dioxide Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 17:37 Last Updated: October 07, 2023 at 17:37
PW128525 View Pathway	drug action Tivozanib Action Pathway Homo sapiens Tivozanib, marketed as FOTIVDA, is a kinase inhibitor primarily used to treat renal cell carcinoma (RCC) in adult patients who have not responded to previous systemic therapies or have experienced relapsed disease. RCC is a relatively common cancer that predominantly affects adults between the ages of 65 to 74. Tivozanib offers hope as a therapeutic option for individuals with advanced RCC who have not had success with other treatments. It is approved in the United States for those who have undergone two or more systemic therapies for RCC. In the UK and some other countries, it is indicated as the first-line therapy for adults with advanced RCC who have not previously received VEGFR and mTOR pathway inhibitors after their disease has progressed following one prior treatment with cytokine therapy. Tivozanib works by inhibiting growth factor receptors, specifically targeting renal cell carcinoma. In preclinical studies using mice and rats, tivozanib demonstrated its ability to inhibit tumor angiogenesis, slow tumor growth, and reduce vascular permeability. However, it's important to note that tivozanib can often lead to hypertension, which must be managed before initiating therapy. Additionally, while a cardiac QT segment prolongation was reported in a tivozanib cardiac safety study, these reactions were not deemed clinically serious. Furthermore, clinical studies have shown a decrease in serum soluble VEGFR2 (sVEGFR2) levels over time with tivozanib exposure, and sVEGFR2 can serve as a pharmacodynamic marker of VEGFR inhibition. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Dorsa Yahya Rayat Created On: September 01, 2023 at 13:19 Last Updated: September 01, 2023 at 13:19
PW132519 View Pathway	metabolic Tivozanib Drug Metabolism Homo sapiens Tivozanib is a drug that is not metabolized by the human body as determined by current research and biotransformer analysis. Tivozanib passes through the liver and is then excreted from the body mainly through the kidney. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: September 21, 2023 at 22:14 Last Updated: September 21, 2023 at 22:14
PW146453 View Pathway	drug action Tivozanib Drug Metabolism Action Pathway Homo sapiens BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: October 07, 2023 at 18:14 Last Updated: October 07, 2023 at 18:14
PW127597 View Pathway	drug action Tixagevimab Action Pathway Homo sapiens Tixagevimab is an extended half-life recombinant monoclonal IgG1κ antibody directed against the SARS-CoV-2 S protein for COVID-19 prophylaxis in individuals unable to undergo COVID-19 immunization.Tixagevimab, in combination with cilgavimab, was issued an FDA emergency use authorization on December 9, 2021. The combination of drugs was packaged as EVUSHELD and was granted marketing authorization by the EMA on March 28, 2022, then it was approved in Canada later on April 14, 2022. Certain SAR-CoV-2 Omicron subvariants may be associated with resistence to EVUSHELD. SARS-CoV-2 enters host cells via the interaction between the trimeric spike (S) glycoprotein and host cell angiotensin-converting enzyme 2 (ACE2). Cilgavimab inhibits S glycoprotein by blocking the interaction between it and the host ACE2 protein. This inhibits the binding and entry of the virion into the host cell. This prevents viral replication and propagation. BioPAX SVG SBGN SBML PWML All files (.zip)	Creator: Ray Kruger Created On: May 12, 2023 at 09:54 Last Updated: May 12, 2023 at 09:54